Patrocinadores de la SETGyC



VIVEbiotech is a Company fully focused on Lentiviral vectors with two main activities: CDMO: GMP Contract Development and Manufacturing Organization specialized in Lentiviral vectors. VIVEbiotech is focused on the manufacture of Research, Preclinical toxicology and GMP-grade lentiviral vectors.
Sealed as Excellence Centre by European Union, VIVEbiotech is currently working with Companies based both in Europe and USA being our main aim adapting to customer requirements considering also planning and timelines related aspects.
Own Technology development: LENTISOMA: VIVEbiotech has developed its own worldwide licensed technology, a non-integrative episomal replicative lentiviral vector whose main advantage is associated to safety-related aspects


In the early 80s’ the establishment of CELBIO represented a true milestone, as this Company quickly became a reference for a number of scientists, giving them a valuable opportunity to gain access to a world of products and equipment in Biotechnology. Later on, this name became familiar also in the Medical and Diagnostic field. This leading approach remained unchanged and possibly improved throughout almost three decades, reinforcing the image of this Company as a reliable and solid partner for the entire scientific community.

At the beginning of the 90s' a sister Company called Euroclone® started its activity with the goal of giving more emphasis to the development of smart ideas which were felt to evolve into nice products to sell. The success was such that in 2009 it was decided to merge the two Companies, and CELBIO was fully incorporated into Euroclone®.

As a matter of fact, Euroclone® nowadays is bringing into the market the “passion” of the early days (since has inherited the Distribution of a panel of well known brands) along with a clear and growing interest in innovative and state-of-the art technologies originated by in-house R&D as well as obtained under private label and OEM agreement with the most qualifi ed manufacturers worldwide.

In other words, Euroclone® continues the tradition of CELBIO, while evolving into a modern supplier of up-to-date and own-branded products, thus reconfirming its position as a key-provider for a number of laboratories and clinics.



Genethon, created by AFM-Telethon, has the mission to make innovative  gene therapy treatments available to patients affected with rare genetic diseases. To meet this challenge Genethon has assembled the technical and human resources needed to accelerate the medical application of scientific discoveries arising from fundamental research. Strong translational research programs engage multi-disciplinary teams and are supported by a first rate technological platform and cGMP facility

The pipeline of Genethon includes products currently in international clinical trials and at preclinical stages, for muscular dystrophies, immune deficiencies, blood, ocular and liver diseases. These products are developed either with Genethon as sponsor, or in partnership with private companies and academic institutions.

Plasmid Factory

PlasmidFactory GmbH & Co. KG is a biopharmaceutical company, founded in Bielefeld in 2000.

Today the company is formed by a team of biologists, chemists, engineers and technicians. PlasmidFactory is the leading contract manufacturer of plasmid and minicircle DNA.

We produce your plasmids and minicircles according to your requirements in modern laboratories with high quality standards.

We are focussing R&D activities on our core competences: Production, analysis and storage of plasmid DNA.

At present, we are working on the following research topics – in close co-operation with industrial and academic partners.

  • Development of non-viral vector systems free of resistence gene sequences (minicircle)
  • Research on long-term storage of plasmid DNA and parameters influencing the stability (e.g. plasmid size, DNA concentration, storage buffer)
  • Influence of freeze and thaw conditions on plasmid topology
  • DNA vaccine development for cat fibrosarcoma
  • Production of dimer or multimer plasmids (e.g. reporter gene vectors)
  • Application of capillary gel electrophoresis (CGE) 
  • Optimization of vectors for co-transfection, e.g. for production of viruses (AAV, LV) or antibodies
  • Optimization of lentiviral vector systems
  • Vector development for hepatitis vaccines
  • Clinical and pre-clinical research for non-viral vectors
  • Microfluidic channel for separating minicircle and miniplasmids.